ArticleFrontiers in medicine2022
A New Predictive Model for the Prognosis of MDA5
Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Predictors of rapidly progressive interstitial lung disease in anti-MDA5 dermatomyositis: a meta-analysis.Rheumatology (Oxford, England) · 2026Pooled it
- Risk factors for mortality in anti-MDA5 antibody-positive dermatomyositis with interstitial lung disease: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Clinical characteristics and long-term prognosis of anti-MDA5-positive dermatomyositis: a comparative study across age groups.Orphanet journal of rare diseases · 2026Article
- Prognostic value of HRCT-based risk stratification for acute/subacute progression in polymyositis/dermatomyositis-associated interstitial lung disease.Frontiers in immunology · 2026Article
- The clinical features and mortality predictors for idiopathic inflammatory myopathies: a retrospective study of 572 patients and the "AIRMT" Score.Clinical rheumatology · 2025Article
- Identifying two pathways to poor prognosis in patients with anti-MDA5 antibodies: insights from prognostic factor and cytokines analysis.Arthritis research & therapy · 2025Article
- Mortality Risk Prediction in Patients With Antimelanoma Differentiation-Associated, Gene 5 Antibody-Positive, Dermatomyositis-Associated Interstitial Lung Disease: Algorithm Development and Validation.Journal of medical Internet research · 2025Article
- Monocyte-macrophage dynamics as key in disparate lung and peripheral immune responses in severe anti-melanoma differentiation-associated gene 5-positive dermatomyositis-related interstitial lung disease.Clinical and translational medicine · 2025Article
- Clinical features and recurrence risk prediction model in patients with idiopathic inflammatory myopathies-associated interstitial lung disease: a retrospective study from Ningbo.Frontiers in medicine · 2025Article
- Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis Without Cutaneous Findings or Rapidly Progressive Lung Disease: A Case Report.Journal of general internal medicine · 2024Article
- Predictors of relapse of polymyositis/dermatomyositis associated interstitial lung disease.Journal of thoracic disease · 2024Article
- [A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- Article
- MDA5-positive dermatomyositis without muscle weakness and rash: a case report and literature review.Frontiers in medicine · 2024Article
- The diagnosis and management of systemic autoimmune rheumatic disease-related interstitial lung disease: British Society for Rheumatology guideline scope.Rheumatology advances in practice · 2024Review
- Predictors of rapidly progressive interstitial lung disease and prognosis in Chinese patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study is to analyze clinical information and combine significant parameters to generate a predictive model and achieve a better prognosis prediction of dermatomyositis-associated interstitial lung disease with positive melanoma differentiation-associated gene 5 antibody (MDA5 Methods: We retrospectively reviewed 63 patients MDA5 Results: In all the 63 patients with MDA5 Conclusion: We demonstrated that duration, fever, PE, TCTs, and AST could be integrated together to be independent predictors of poor prognosis in MDA5
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.